MA38816B1 - Sulfamidase modifiée et sa production - Google Patents

Sulfamidase modifiée et sa production

Info

Publication number
MA38816B1
MA38816B1 MA38816A MA38816A MA38816B1 MA 38816 B1 MA38816 B1 MA 38816B1 MA 38816 A MA38816 A MA 38816A MA 38816 A MA38816 A MA 38816A MA 38816 B1 MA38816 B1 MA 38816B1
Authority
MA
Morocco
Prior art keywords
sulfamidase
modified
production
relates
present
Prior art date
Application number
MA38816A
Other languages
English (en)
Other versions
MA38816A (fr
Inventor
Charlotta Berghard
Erik Nordling
Gelius Stefan Svensson
Agneta Tjernberg
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of MA38816A publication Critical patent/MA38816A/fr
Publication of MA38816B1 publication Critical patent/MA38816B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une sulfamidase modifiée, une composition comprenant une sulfamidase modifiée, ainsi que des procédés de préparation d'une sulfamidase modifiée et l'utilisation thérapeutique d'une telle sulfamidase. En particulier, la présente invention concerne une sulfamidase modifiée ne comprenant pratiquement pas d'épitopes pour des récepteurs de reconnaissance de glycane, permettant ainsi le transport de ladite sulfamidase à travers la barrière hémato-encéphalique d'un mammifère, ladite sulfamidase ayant une activité catalytique dans le cerveau dudit mammifère.
MA38816A 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production MA38816B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162996 2014-04-01
PCT/EP2015/057256 WO2015150490A1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et son procédé de production
EP15713502.1A EP2970413B1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production

Publications (2)

Publication Number Publication Date
MA38816A MA38816A (fr) 2016-01-20
MA38816B1 true MA38816B1 (fr) 2018-10-31

Family

ID=50389999

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38816A MA38816B1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production

Country Status (30)

Country Link
US (2) US9982243B2 (fr)
EP (2) EP2970413B1 (fr)
JP (1) JP6594896B2 (fr)
KR (1) KR20160138282A (fr)
CN (1) CN106414727A (fr)
AU (1) AU2015239126B2 (fr)
BR (1) BR112016022333A2 (fr)
CA (1) CA2943140A1 (fr)
CL (1) CL2016002469A1 (fr)
CY (1) CY1120697T1 (fr)
DK (1) DK2970413T3 (fr)
ES (1) ES2687262T3 (fr)
HK (1) HK1231510A1 (fr)
HR (1) HRP20181507T1 (fr)
HU (1) HUE039691T2 (fr)
IL (1) IL247978A0 (fr)
LT (1) LT2970413T (fr)
MA (1) MA38816B1 (fr)
MX (1) MX368947B (fr)
PH (1) PH12016501812A1 (fr)
PL (1) PL2970413T3 (fr)
PT (1) PT2970413T (fr)
RS (1) RS57842B1 (fr)
RU (1) RU2708026C2 (fr)
SA (1) SA516371859B1 (fr)
SG (1) SG11201608025QA (fr)
SI (1) SI2970413T1 (fr)
UA (1) UA120432C2 (fr)
WO (1) WO2015150490A1 (fr)
ZA (1) ZA201606492B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120432C2 (uk) 2014-04-01 2019-12-10 Сведіш Орфан Біовітрум Аб (Пабл) Модифікована сульфамідаза і її одержання
WO2017055570A1 (fr) * 2015-10-01 2017-04-06 Swedish Orphan Biovitrum Ab (Publ) Protéine lysosomale modifiée et sa production
CA3076369A1 (fr) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Proteines de fusion comprenant des enzymes d'enzymotherapie substitutive
WO2019145500A1 (fr) 2018-01-26 2019-08-01 Swedish Orphan Biovitrum Ab (Publ) Méthode de traitement
WO2020047282A1 (fr) 2018-08-29 2020-03-05 University Of Copenhagen Enzymes lysosomales modifiées par glyco-ingénierie basée sur les cellules
EP3741867A1 (fr) 2019-05-24 2020-11-25 Swedish Orphan Biovitrum AB (Publ) Dosage d'activité de sulfatase
KR20230086703A (ko) 2020-10-14 2023-06-15 데날리 테라퓨틱스 인크. 설포글루코사민 설포하이드롤라제 효소를 포함하는 융합 단백질 및 이의 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
CA2257357C (fr) 1996-06-07 2010-04-13 Neorx Corporation Anticorps humanises a glycosylation modifiee
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
AU2002362930A2 (en) 2001-10-16 2003-04-28 Zystor Therapeutics, Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
EP1552298A4 (fr) 2002-07-01 2006-11-08 Kenneth S Warren Inst Inc Cytokines protectrices des tissus recombinees et acides nucleiques codants associes pour la protection, la restauration et l'amelioration de cellules, de tissus et d'organes sensibles
EP2139912A2 (fr) * 2007-03-06 2010-01-06 Saint Louis University Enzyme modifiée et procédé de traitement
PT2245145T (pt) * 2008-01-18 2017-03-14 Biomarin Pharm Inc Fabrico de enzimas sulfatase lisossómicas humanas altamente fosforiladas e suas utilizações
EP2394667A1 (fr) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vecteurs et séquences pour le traitement de maladies
AU2010366066B2 (en) 2010-12-22 2016-01-14 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
WO2012177778A1 (fr) * 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Thérapie anti-tnf contre les mucopolysaccharidoses et d'autres maladies lysosomiales
WO2014194427A1 (fr) 2013-06-06 2014-12-11 Angiochem Inc. Protéines de fusion iduronate-2-sulfatase ciblées
US20140377246A1 (en) 2013-06-19 2014-12-25 Carol Ann Foundation and International Morquio Organization Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme
UA120432C2 (uk) 2014-04-01 2019-12-10 Сведіш Орфан Біовітрум Аб (Пабл) Модифікована сульфамідаза і її одержання

Also Published As

Publication number Publication date
CL2016002469A1 (es) 2017-12-15
MX2016012910A (es) 2017-07-14
SI2970413T1 (sl) 2018-10-30
PL2970413T3 (pl) 2018-12-31
RU2016140844A (ru) 2018-05-10
WO2015150490A1 (fr) 2015-10-08
CN106414727A (zh) 2017-02-15
RS57842B1 (sr) 2018-12-31
DK2970413T3 (en) 2018-10-15
CA2943140A1 (fr) 2015-10-08
JP2017514462A (ja) 2017-06-08
RU2016140844A3 (fr) 2018-10-11
RU2708026C2 (ru) 2019-12-03
UA120432C2 (uk) 2019-12-10
JP6594896B2 (ja) 2019-10-23
AU2015239126A1 (en) 2016-10-27
US9982243B2 (en) 2018-05-29
PH12016501812A1 (en) 2017-07-24
HK1231510A1 (zh) 2017-12-22
ES2687262T3 (es) 2018-10-24
SA516371859B1 (ar) 2019-01-17
US20160230155A1 (en) 2016-08-11
EP2970413A1 (fr) 2016-01-20
EP2970413B1 (fr) 2018-07-04
MA38816A (fr) 2016-01-20
HUE039691T2 (hu) 2019-01-28
LT2970413T (lt) 2018-10-10
SG11201608025QA (en) 2016-10-28
PT2970413T (pt) 2018-10-23
ZA201606492B (en) 2019-02-27
HRP20181507T1 (hr) 2018-11-16
US20180320152A1 (en) 2018-11-08
IL247978A0 (en) 2016-11-30
BR112016022333A2 (pt) 2017-08-15
MX368947B (es) 2019-10-22
CY1120697T1 (el) 2019-12-11
AU2015239126B2 (en) 2019-05-02
KR20160138282A (ko) 2016-12-02
EP3401325A1 (fr) 2018-11-14

Similar Documents

Publication Publication Date Title
MA38816B1 (fr) Sulfamidase modifiée et sa production
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
MD3555064T2 (ro) Agoniști ai receptorului GLP-1 și utilizările acestora
BR112014026755A2 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MD3273992T2 (ro) Anticorpi pentru ICOS
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
MA39362A1 (fr) Compositions stables d'iode non complexé et procédés d'utilisation.
EA201491391A1 (ru) Терапевтически активные соединения и способы их применения
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
BR112015004029A2 (pt) Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201790432A1 (ru) Зонды для визуализации белка хантингтина